Vanda Pharmaceuticals reported a 24% increase in Q3 2026 revenues to $69.8 million and an 18% decrease in operating expenses compared to Q2 2026, driven by strong sales of Fanapt and the commercial launch of NEREUS. The company announced positive Phase III results for NEREUS in preventing GLP-1-induced vomiting and expects to launch BYSANTI in Q4 2026. The FDA is reviewing Quimilza with a decision expected by December 12, 2026. Vanda aims to moderate costs further while expanding its product portfolio and expects full-year 2026 revenues to exceed $240 million.
Vanda Pharmaceuticals' Q3 2026 financial results provide context for health sector performance. For readers following health stocks, here is Pluang's market snapshot as of Oct 29, 2026 02:12 WIB: Among 150 priced US health-sector stocks, 87 rose and 62 fell today. Notable movers include Butterfly Network Inc. Class A Common Stock (BFLY) at USD 7.76 with a +5.15% change and a typical hold time of 14 days, Alumis Inc. Common Stock (ALMS) at USD 6.98 with a +5.12% change and a 14-day hold, and Hims and Hers Health Inc (HIMS) at USD 29.26 with a +4.80% change, 88% buy order activity, and a typical hold time of 23 days.
SpaceX reported a strong Q3 with revenue up 161% year-over-year to $14.6 billion and a net profit of $4.4 billion, reversing last year's loss. Starlink, its satellite internet service, grew revenue by nearly 70% to $5.2 billion and added 1.6 million ...
SPIE, a leading European multi-technical services provider, has signed an agreement to acquire a 76% stake in SAR ANLAGENBAU GmbH, a major electrical engineering and automation firm based in Austria and Germany. This acquisition will enhance SPIE's p...
SPIE, a European leader in energy and communication services, has agreed to acquire a 76% stake in SAR ANLAGENBAU GmbH, a key electrical engineering and automation firm in Austria and Germany. This acquisition will broaden SPIE's service portfolio in...
The global dermatological therapeutics market is projected to grow from about $43 billion in 2025 to $97 billion by 2034, with a compound annual growth rate of around 10%. This growth is fueled by increasing cases of acne, psoriasis, and other chroni...
Blockchain.com has launched TRX options trading, providing easier access to TRON's native token through its platform. This move expands the TRON ecosystem's reach by simplifying options trading for retail and institutional users worldwide. TRON, know...
